AU2013352223B2 - Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase I inhibitor - Google Patents
Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase I inhibitor Download PDFInfo
- Publication number
- AU2013352223B2 AU2013352223B2 AU2013352223A AU2013352223A AU2013352223B2 AU 2013352223 B2 AU2013352223 B2 AU 2013352223B2 AU 2013352223 A AU2013352223 A AU 2013352223A AU 2013352223 A AU2013352223 A AU 2013352223A AU 2013352223 B2 AU2013352223 B2 AU 2013352223B2
- Authority
- AU
- Australia
- Prior art keywords
- treatment
- long
- inhibitor
- topoisomerase
- tumor marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCC(CC(COCC(CC(*)OCCC(C)(C)OCC(NCC(*C)=O)=O)*OCC*OCC(NCC(*C)=O)=O)*1(CC1)OCC*(C)OCC(NCC(C)=O)=O)OCCC(C)(C)OCC(NCC(*)=O)=O Chemical compound CCC(CC(COCC(CC(*)OCCC(C)(C)OCC(NCC(*C)=O)=O)*OCC*OCC(NCC(*C)=O)=O)*1(CC1)OCC*(C)OCC(NCC(C)=O)=O)OCCC(C)(C)OCC(NCC(*)=O)=O 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4725—Mucins, e.g. human intestinal mucin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261730900P | 2012-11-28 | 2012-11-28 | |
| US61/730,900 | 2012-11-28 | ||
| PCT/US2013/072205 WO2014085571A1 (en) | 2012-11-28 | 2013-11-27 | Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase i inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013352223A1 AU2013352223A1 (en) | 2015-05-21 |
| AU2013352223B2 true AU2013352223B2 (en) | 2019-07-18 |
Family
ID=49753531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013352223A Active AU2013352223B2 (en) | 2012-11-28 | 2013-11-27 | Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase I inhibitor |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10132810B2 (enExample) |
| EP (1) | EP2926137B1 (enExample) |
| JP (1) | JP6284541B2 (enExample) |
| KR (1) | KR102120510B1 (enExample) |
| CN (1) | CN104813167B (enExample) |
| AU (1) | AU2013352223B2 (enExample) |
| CA (1) | CA2890082C (enExample) |
| ES (1) | ES2731725T3 (enExample) |
| MX (1) | MX366911B (enExample) |
| WO (1) | WO2014085571A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106191022B (zh) * | 2016-02-22 | 2019-08-20 | 叶尚勉 | 一种肿瘤特异抗原及其应用 |
| US11253603B2 (en) | 2018-09-17 | 2022-02-22 | The Children's Hospital Of Philadelphia | Polymer-based macromolecular prodrugs |
| CN112102914A (zh) * | 2020-09-25 | 2020-12-18 | 复旦大学附属肿瘤医院 | 曲妥珠单抗生物类似药的评价方法及系统 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110269789A1 (en) * | 2008-09-23 | 2011-11-03 | Nektar Therapeutics | Compositions and Methods for Achieving Sustained Therapeutic Drug Concentrations in a Subject |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9704444D0 (en) * | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| US6355623B2 (en) * | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| US20020103141A1 (en) * | 1998-12-23 | 2002-08-01 | Mckearn John P. | Antiangiogenic combination therapy for the treatment of cancer |
| US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| CN1852740B (zh) | 2003-09-17 | 2011-05-11 | 耐科塔医药公司 | 多支链聚合物的药物前体 |
| JP2007526455A (ja) * | 2004-02-03 | 2007-09-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法 |
| EP1928484B1 (en) * | 2005-08-26 | 2010-02-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of headaches by administration of oxytocin |
| CA2640013A1 (en) * | 2006-02-09 | 2007-08-16 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| US20110151580A1 (en) * | 2007-11-06 | 2011-06-23 | University Health Network | Method for the detection of breast cancer by determining alcam and/or bcam levels in a patient |
| EP2501412B1 (en) | 2009-11-18 | 2017-03-29 | Nektar Therapeutics | Salt form of a multi-arm polymer-drug conjugate |
| CA2795776A1 (en) * | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| WO2012031320A1 (en) | 2010-09-06 | 2012-03-15 | Peter Maccallum Cancer Institute | Cancer diagnostic |
| US20140378404A1 (en) | 2011-10-25 | 2014-12-25 | Nektar Therapeutics | Treatment of Patients Suffering from Cancer |
-
2013
- 2013-11-27 WO PCT/US2013/072205 patent/WO2014085571A1/en not_active Ceased
- 2013-11-27 JP JP2015544204A patent/JP6284541B2/ja active Active
- 2013-11-27 ES ES13802833T patent/ES2731725T3/es active Active
- 2013-11-27 KR KR1020157013659A patent/KR102120510B1/ko active Active
- 2013-11-27 CN CN201380061709.6A patent/CN104813167B/zh active Active
- 2013-11-27 AU AU2013352223A patent/AU2013352223B2/en active Active
- 2013-11-27 CA CA2890082A patent/CA2890082C/en active Active
- 2013-11-27 US US14/648,042 patent/US10132810B2/en active Active
- 2013-11-27 MX MX2015006733A patent/MX366911B/es active IP Right Grant
- 2013-11-27 EP EP13802833.7A patent/EP2926137B1/en active Active
-
2018
- 2018-10-03 US US16/151,115 patent/US20190049450A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110269789A1 (en) * | 2008-09-23 | 2011-11-03 | Nektar Therapeutics | Compositions and Methods for Achieving Sustained Therapeutic Drug Concentrations in a Subject |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016502083A (ja) | 2016-01-21 |
| JP6284541B2 (ja) | 2018-02-28 |
| MX2015006733A (es) | 2015-08-14 |
| CN104813167B (zh) | 2019-04-09 |
| KR20150089013A (ko) | 2015-08-04 |
| WO2014085571A1 (en) | 2014-06-05 |
| US20190049450A1 (en) | 2019-02-14 |
| MX366911B (es) | 2019-07-30 |
| KR102120510B1 (ko) | 2020-06-08 |
| ES2731725T3 (es) | 2019-11-18 |
| US10132810B2 (en) | 2018-11-20 |
| CN104813167A (zh) | 2015-07-29 |
| CA2890082C (en) | 2021-07-06 |
| US20150309032A1 (en) | 2015-10-29 |
| EP2926137B1 (en) | 2019-05-29 |
| AU2013352223A1 (en) | 2015-05-21 |
| EP2926137A1 (en) | 2015-10-07 |
| CA2890082A1 (en) | 2014-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11844795B2 (en) | Combination therapy for cancer treatment | |
| Prados et al. | Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study | |
| US20090181997A1 (en) | Therapeutic cancer treatments | |
| US20190049450A1 (en) | Method for Assessing and Predicting Efficacy of Breast Cancer Treatment with a Long-Acting Topoisomerase I Inhibitor | |
| Maity et al. | Targeting the epidermal growth factor receptor with molecular degraders: state-of-the-art and future opportunities | |
| US20180095085A1 (en) | Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents | |
| Posey III et al. | Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas | |
| US20100222287A1 (en) | Therapeutic Cancer Treatments | |
| CA3206523A1 (en) | Use of a kras g12c inhibitor in treating cancers | |
| Lian et al. | RJT-101, a novel camptothecin derivative, is highly effective in the treatment of melanoma through DNA damage by targeting topoisomerase 1 | |
| JP6138140B2 (ja) | 癌患者の治療 | |
| Burns et al. | Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC | |
| CN114126656A (zh) | 治疗癌症的方法和用途 | |
| Montemurro et al. | The 41st Annual Meeting of The American Society of Clinical Oncology: Orlando, FL, USA, 13–17 May, 2005 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |